U.S. markets closed

TELA Bio, Inc. (TELA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
13.20-0.18 (-1.35%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Momentum

Momentum

Previous Close13.38
Open13.25
Bid10.50 x 800
Ask23.99 x 900
Day's Range12.97 - 13.45
52 Week Range5.25 - 23.55
Volume25,662
Avg. Volume95,307
Market Cap190.18M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-6.48
Earnings DateAug 12, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est19.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      TELA Bio to Participate at the Canaccord Genuity 40th Annual Growth Conference

      MALVERN, Pa., July 30, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, announces today it will be participating in the Canaccord Genuity 40th Annual Growth Conference, scheduled to be held virtually August 11-13, 2020. TELA Bio's management is scheduled to present on Thursday, August 13, 2020, at 1:30 p.m. Eastern Time. Interested parties may access a live audio webcast of the presentation by visiting the "Investors" section of the company's website at ir.telabio.com. About TELA Bio, Inc.TELA Bio, Inc. is a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. TELA's products are designed to improve on shortcomings of existing biologics and minimize long-term exposure to permanent synthetic material. TELA's portfolio is supported by quality, data-driven science and extensive pre-clinical research that has consistently demonstrated advantages over other commercially available products.TELA Bio Contact Stuart Henderson Vice President, Corporate Development and Investor Relations TELA Bio, Inc. 484-320-2930 Investor Contact Greg Chodaczek 347-620-7010  ir@telabio.com

    • GlobeNewswire

      TELA Bio to Announce Second Quarter 2020 Financial Results and Host Conference Call on August 12, 2020

      MALVERN, Pa., July 23, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, announced that the company will report 2020 second quarter financial results on August 12, 2020. TELA Bio's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update.  Conference Call and Webcast Details The conference call can be accessed by dialing (855) 548-1219 for participants in the U.S. or Canada and (409) 217-8881 for international callers, using conference ID 6897439. A live and archived webcast of the event can be accessed via the Events & Presentations page of the investor section of TELA's website.About TELA Bio, Inc. TELA Bio, Inc. is a commercial stage medical technology company focused on designing, developing, and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. TELA Bio's products are designed to improve on shortcomings of existing biologics and minimize long-term exposure to permanent synthetic material. TELA Bio's portfolio is supported by quality, data-driven science, and extensive pre-clinical research that has consistently demonstrated advantages over other commercially available products.TELA Bio Contact Stuart Henderson Vice President, Corporate Development and Investor Relations TELA Bio, Inc. 484-320-2930 Investor Contact Greg Chodaczek 347-620-7010  ir@telabio.com

    • GlobeNewswire

      TELA Bio Announces Closing of Public Offering of Common Stock

      TELA Bio, Inc. (“TELA”), a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced the closing of its underwritten public offering of 3,000,000 shares of its common stock at a public offering price of $16.00 per share, for gross proceeds of $48.0 million, before underwriting discounts and commissions. In addition, TELA has granted the underwriters a 30-day option to purchase up to 450,000 additional shares of common stock in the offering. Canaccord Genuity LLC acted as lead manager and JMP Securities LLC acted as co-manager.